In this series, we will be introducing one-by-one the new members that have joined our ecosystem in the last six months. Follow us for a new article next week!
We are proud to present one of the latest additions to our cluster – Hubro Therapeutics.
Hubro Therapeutics is a Norwegian biotech start-up from 2018 that develops immunotherapies against cancer. These treatments aim to trigger the body’s immune system to fight cancer. The company is currently situated in Oslo Cancer Cluster Incubator, where they are using the laboratory facilities to develop their treatments.
We talked with Jon Amund Eriksen, founder and CEO of Hubro Therapeutics, to find out a little bit more about the company, their work in cancer research and the reason why they joined Oslo Cancer Cluster.
Could you briefly describe Hubro Therapeutics and the role you take in cancer?
“Hubro Therapeutics AS is a biotech company based on thirty years of R&D experience in the field of immunotherapy of cancer. The company is specialising in developing peptide vaccines targeting shared cancer specific neo-antigens, focusing on design and development of novel peptides and peptide compositions for targeting frameshift mutations in micro-satellite instable (msi) cancers. The lead candidate vaccine targeting frameshift mutation in TGFbR2 is currently in development for clinical testing in msi-colorectal cancer and potentially msi-gastric cancer,” said Jon Amund Eriksen, founder and CEO.
Why did you join Oslo Cancer Cluster?
“For us, Oslo Cancer Cluster with its incubator and laboratory facilities provides a perfect opportunity to operate in a highly relevant and focused scientific environment as well as to generate our own experimental results without heavy investments,” said Jon Amund Eriksen, founder and CEO.
- Visit Hubro Therapeutics official website
- Listen to Episode 92 of the Radium podcast, when Jon Amund Eriksen was interviewed in the studio